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Pharmacological Approaches to Antitrypanosomal
Chemotherapy
Simon L Croft
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel
Street, London WC1E 7HT, UK
There is an urgent need for new drugs for the chemotherapy of  human African trypanosomiasis,
Chagas disease and leishmaniasis. Progress has been made in the identification and characterization of
novel drug targets for rational chemotherapy and inhibitors of trypanosomatid glycosomal enzymes,
trypanothione reductase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, cysteine pro-
teases and of the purine and sterol biosynthetic pathways. However, less attention has been paid to the
pharmacological aspects of drug design or to the use of drug delivery systems in the chemotherapy of
African trypanosomiasis and Chagas disease. A review of research on pharmacology and drug delivery
systems shows that there are new opportunities for improving the chemotherapy of these diseases.
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Arsenical and antimonial drugs were amongst
the first synthetic drugs to be introduced for infec-
tious diseases in the first two decades of this cen-
tury. It is remarkable that organic derivatives of
these heavy metals remain the recommended drugs
for the treatment of, respectively, human African
trypanosomiasis (sleeping sickness or HAT) and
leishmaniasis. No drugs became available for the
treatment of Chagas disease until the 1970’s when
two nitroheterocyclic drugs, nifurtimox and
benznidazole, were introduced. All the drugs rec-
ommended for the treatment of the trypanosomi-
ases and the leishmaniases have limitations, includ-
ing either variable efficacy, toxicity, requirements
for long courses of parenteral administration, re-
sistance and problems of supply, or a combination
of these factors. Although there are several drugs
on trial for the chemotherapy of human leishma-
niasis many are new formulations of old drugs.
There are few drugs of promise for either HAT or
Chagas disease and the situation is precarious (De
Castro 1993, Wang 1995, Croft et al. 1997).
A major focus for the discovery of novel
antitrypanosomal and antileishmanial drugs dur-
ing the past two decades has been the identifica-
tion and characterization of biochemical and mo-
lecular targets. Rational approaches to chemo-
therapy have investigated several targets in detail
including the sterol biosynthetic pathway in Try-
panosoma cruzi, ornithine decarboxylase in the T.
brucei complex, trypanothione reductase in Try-
panosoma and Leishmania spp., nucleoside
phosphotransferases in Trypanosoma and Leish-
mania spp., glycosomal enzymes in the T. brucei
complex, cysteine proteases in T. cruzi and Leish-
mania,  folate metabolism and  DNA topoiso-
merases (see Hunter 1997, Wang 1997 and other
references in Coombs & Croft 1997). Several tar-
gets have been characterised structurally and the
design of specific inhibitors is well underway .
In contrast the pharmacological aspects of drug
design that include aspects to improve drug up-
take, activation by pathogen or host cells, absorp-
tion and distribution in the host (Gumbleton &
Sneader 1994, Navia & Chatuverdi 1996) have
received less attention. Most reported research in
this area have focused on the chemotherapy of
leishmaniasis and not the trypanosomiases, includ-
ing studies on quantitative structure activity rela-
tionships to improve lipophilicity and activity
(Booth et al. 1987), the lysosomotropic properties
of amino acid and dipeptide esters and bis
(benzyl)polyamine analogues to enhance accumu-
lation by the Leishmania infected phagosome
(Rabinovitch 1989, Baumann et al. 1991), and car-
rier molecules to aid targetting of drug to parasite
or parasite host cell, for example allopurinol-
glycosylated polymers to receptors on Leishma-
nia infected macrophages (Negre et al. 1992).  Drug
delivery systems (cellular, particulate and vesicu-
lar) designed to enhance drug targeting to infected
tissues, reduce metabolism by the host or toxicity
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to the host, or  enable sustained release of drug
within the host have also been explored for the
treatment of  leishmaniasis. The most successful
application of drug delivery systems has certainly
been the use of lipid amphotericin B formulations
for visceral leishmaniasis both in experimental
models (Croft et al. 1991, Berman et al. 1992) and
clinical trials (Berman et al. 1998); liposomes have
also proved effective in experimental cutaneous
leishmaniasis (Yardley & Croft 1997). Alterna-
tively, nanoparticles incorporating primaquine and
pentamidine have also shown to be useful drug
carriers in experimental visceral leishmaniasis
(Rodrigues et al. 1994). So if these approaches can
benefit the chemotherapy of leishmaniasis, why not
also the chemotherapy of the trypanosomiases?
HUMAN AFRICAN TRYPANOSOMIASIS
In the first stages of HAT parasites are restricted
to the haemolymphatic system and drugs, namely
pentamidine and suramin are available for the treat-
ment of early stage disease. The major problem in
treatment of HAT is the second stage, character-
ized by the presence of trypanosomes in the Cen-
tral Nervous System (CNF) and the cerebrospinal
fluid (CSF). A re-appraisal of the pharmacokinet-
ics of  the only available drug for the treatment of
both T. b. gambiense or T. b. rhodesiense second
stage disease, the trivalent arsenical melarsoprol
[Mel Bâ ], may help to improve treatment.
Melarsoprol, with a masked reactive arsenoxide
group, is lipid soluble and should gain easy access
to the brain, although suprisingly low levels of drug
have been detected in the CNS, only 0.5 to 5% of
plasma levels (Pepin & Milord 1994). Recom-
mended treatment schedules are of three or four
courses spaced by an interval of at least one week.
It has been suggested that these schedules may not
be the most effective and may also be responsible
in part for the frequently reported side effects, the
most severe being a reactive encephalopathy in up
to 10% of the treated patients with a mortality of
up to 5% (Pepin & Milord 1994). Bioassay and
Elisa techniques (Maes et al. 1988, Burri et al.
1993) have been used to determine drug levels of
melarsoprol and active metabolites in serum and
CSF and an elimination half life time of 35 hr in
the blood (Burri et al. 1993). Since blood levels
decreased to zero in between the courses, an alter-
native treatment protocol consisting of 10 consecu-
tive daily doses  has been suggested and a prelimi-
nary clinical study in Zaire gave promising results
with the 10-day regime (Burri et al. 1995). A full
clinical evaluation is now underway. A re-exami-
nation of the pharmacokinetics of pentamidine, a
highly charged diamidine that should not cross the
blood-brain barrier (BBB) and is ineffective against
second stage disease, was suprisingly detected at
0.5-0.8% of plasma levels in the CSF (Bronner et
al. 1991).  This penetration of the CNS may be
due to a breakdown of the blood-brain barrier
(BBB) resulting from the inflammatory response
that accompanies the CNS infection. Eflornithine,
or DL-a-difluoromethylornithine (DFMO), the
only new drug to be developed for the treatment
of late-stage HAT since the introduction of
melarsoprol in 1949, was registered for use in the
early 1990s and has been used to treat many T. b.
gambiense cases including many melarsoprol-re-
fractory cases (Pepin & Milord 1994). Eflornithine
shows excellent penetration into the CNS and high
levels have been detected in CSF compared to
plasma levels in adults, although lower levels were
detected in the CSF of children (Milord et al. 1993).
The inactivity of eflornithine against East African
sleeping sickness is due to innate tolerance of T. b.
rhodesiense to the drug (Iten et al. 1995) and not
CNS penetration.
The BBB describes the continuous tight junc-
tions between the endothelial cells of the cerebral
capillaries that restrict the movement of polar sol-
utes into the brain and are important in controlling
the composition of the fluids that bathe the brain.
Although fenestrated capillaries in the choroid
plexus allow a more direct exchange between blood
and brain fluids, this area constitutes only 1/5000
of the total area for exchange of the tight BBB cap-
illaries. This high level of control of access has
clear implications for delivery of drugs to the brain.
However, the BBB is not an inert barrier; there are
special transport systems that enable access of
amino acids, glucose and specific macromolecules
into the brain (Begley 1996). In addition passive
diffusion of low molecular weight lipophilic com-
pounds, for example melarsoprol, is possible. A
vervet monkey model has recently been established
to evaluate the capability of compounds to cross
the BBB (Brun, pers. comm.). Some compounds
found to be highly active in vitro or the acute ro-
dent model of infection, for example the nucleo-
side analogues S-HPMPA (Kaminsky et al. 1996)
and the diamidine trybizine hydrochloride (Bacchi,
pers. comm., Kaminsky & Brun, pers. comm.) have
not been pursued for further development because
of their apparent inability to cross the BBB in this
model (Brun, pers. comm.).
A search for new treatments for other CNS dis-
eases, for example Alzheimer’s and Parkinson’s
diseases and viral infections has focused attention
on novel approaches to improve delivery of drugs
across the BBB. Two such examples for HIV in-
fections of the brain include the design of  lipo-
philic nucleoside derivatives (Ford et al. 1995) and
the conjugation of zidothymidine to a lipophilic
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carrier that crosses the BBB to become more hy-
drophilic and trapped in the brain (Brewster et al.
1997). Peptides, for example somastatin analogues,
have also been designed with enhanced permeabil-
ity (see Begley 1996).  There are many paradigms
that could be included in the design of new drugs
for HAT.  One group of drugs that do cross the
BBB are novel antiprotozoals, the alkyllysophos-
pholipids (ALPs), that include miltefosine,
edelfosine and ilmofosine, active against T. brucei
bloodstream forms in vitro with ED50 values in the
range of 10-40 mM (Croft et al. 1996). Although
they do not appear to be effective against acute T.
brucei infections in mice (Croft & Rock, unpub-
lished) their potential against chronic CNS infec-
tions is being investigated in combination with
other antitrypanosomal drugs, a well established
strategy for looking for CNS activity (Jennings
1993).
The drug targeting approach towards the treat-
ment of African trypanosomiasis has been tested
in model systems, predominantly against T. brucei.
Williamson et al. (1981) observed that the antican-
cer drug daunorubicin was highly active against
T.brucei in vitro but inactive in vivo. Although ini-
tial efforts to improve daunorubicin uptake into
bloodstream form trypanosomes by linking the
drug to DNA were ineffective, further studies us-
ing protein carriers were more successful, possi-
bly through increased uptake by endocytosis and/
or reduced plasma clearance. Daunorubicin was
most active when linked to BSA (as opposed to
ferritin) by a labile covalent linkage (as opposed
to a stable linkage) and 90% animals were cured
(Williamson et al. 1981). This approach was ex-
tended using particulate carriers with daunorubicin
conjugated to agarose beads or adsorbed to
polycyanoacrylate nanoparticles, shown to enter
the parasites via the flagellar pocket and reside in
lysosomal vesicles. In vivo activity of
daunorubicin-nanoparticle formulations was not
promising,  possibly due to retention of drug within
the parasite lysosomes unreleased from the carrier
and unable to access the nuclear target sites
(Golightly et al. 1988).  Unloaded nanoparticles
were shown to have some  antitrypanosomal  ac-
tivity (Lherm et al. 1987, Golightly et al. 1988). In
another approach involving a molecular carrier, the
anticancer drug cisplatin was more effective against
T. congolense in mice when complexed with
polyglutamic acid than when administered free,
probably due to both a longer plasma half-life and
improved uptake (Meshnick et al. 1984). The ap-
plicability of these approaches to the treatment of
T. brucei infections always appeared to be limited
especially in view of the CNS stage of trypanoso-
miasis. However, recent research on the blood-
brain barrier has indicated receptor mediated
transcytosis, and there have been attempts to im-
prove drug uptake using a monoclonal antibody
OX26 to the BBB transferrin receptor as a drug
carrier (Friden et al. 1993). This again opens up an
area for trypanosomiasis research. A range of other
transporters, for example the glucose carrier
GLUT-1  and the system-L transporter of neutral
amino acids could also be exploited for drug de-
sign and delivery across the BBB (see Begley
1996). Most remarkable are the observations that
poly(butyl)cyanoacrylate nanoparticles (230 nm
diameter) coated with the detergent polysorbate-
80 appear to penetrate the BBB and release quan-
tities of drug within the brain (Kreuter et al. 1995,
Schroder & Sabel 1996). A re-examination of the
nanoparticle delivery approach for experimental
CNS trypanosomiasis should be made. Attempts
at drug delivery to the brain using liposomes has
been unsuccessful (see Begley 1996).
Yet another approach used to assist the deliv-
ery of drugs across the BBB to the CNS involves
opening intercellular junctions. Osmotic shock fol-
lowing administration of a hyperosmotic solution,
for example of mannitol, has been used clinically
to increase access of anti-tumour drugs (Neuwelt
& Barnett 1989). An indication of the applicabil-
ity of this approach to T. brucei infections in rats
was demonstrated using hyperosomotic lithium
chloride to increase the level of diminazene
aceturate in the brain of infected animals and to
improve therapy (Odika et al. 1995a,b). A more
recent and sophisticated tactic is based upon re-
ceptor-mediated permeabilization of tight junctions
by bradykinin. A bradykinin agonist, RMP-7, has
been shown to open tight junctions of BBB capil-
laries and enhance drug entry into the brain (Bartus
et al. 1996, Elliott et al. 1996). It is strange in this
context to mention DFMO again. Ornithine decar-
boxylase levels in microvasculature increase fol-
lowing BBB breakdown induced by mannitol;
DFMO reverses BBB breakdown through inhibi-
tion of ornithine decarboxylase (Koenig et al.
1989).
SOUTH AMERICAN TRYPANOSOMIASIS
The wide tissue and cell distribution of intrac-
ellular T. cruzi amastigotes during both the acute
and chronic phases makes Chagas disease a more
difficult subject for drug targeting in comparison
to leishmaniasis where amastigotes are restricted
to macrophages and HAT where there is a defined
problem of the BBB.  Perhaps because of this little
attention has been paid to drug delivery and the
pharmacokinetics of anti-T. cruzi drugs since the
studies of Avila et al. (1979) and Avila (1983).
The lysosomotropic properties of a DNA-
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pharmacophore complex, ethidium bromide-DNA
were initially studied. A suppressive effect of a T.
cruzi Y strain infection of mice was demonstrated
but not cure (Avila et al. 1979). One explanation
offered for this was that T. cruzi amastigotes sur-
vive in host cell cytoplasm whereas the drug was
targeted to the phagosomal compartment and was
not released. Subsequently, 4-amino-pyrazo-
lopyrimidine (APP), a compound similar in struc-
ture to allopurinol which has been on clinical trial
for Chagas’ disease (Gallerano et al. 1990), was
derivatised with glucosamine and conjugated to
BSA. BSA-gluAPP together with BSA-leu-
gluAPP and BSA-ala-leu-gluAPP derivatives had
little activity against T.cruzi Y strain acute infec-
tions in mice. However, albumin-leu-ala-leu-
gluAPP and albumin-ala-leu-ala-leu-gluAPP were
significantly efficacious at 0.1 mg/kg, animals sur-
viving until 250-290 days in comparison to sur-
vival times of 13 days for controls and 52 days for
free drug treated animals. The high activity of these
conjugates parallelled the ability of APP release
from carrier molecule by purified lysosmal en-
zymes (Avila 1983). In a further study formycin
B, another purine analogue, and APP were
adsorbed onto 200 nm polyisobutylcyanoacrylate
nanoparticles. These nanoparticles also signifi-
cantly increased the survival time of T.cruzi Y
acutely infected mice in comparison to free drug
and unloaded carriers which were relatively inef-
fective (Avila  1983). Do any drug delivery sys-
tems offer potential for the treatment of Chagas
disease?
Amphotericin B is highly active against T. cruzi
(De Castro et al. 1994) as these parasites, like fungi
and Leishmania, possess ergosterol as the predomi-
nant membrane sterol to which the drug binds in
preference to cholesterol. However, the use of
amphotericin B in the treatment of mycoses, leish-
maniasis and Chagas disease has been limited by a
wide range of toxic side effects. Lipid amphoteri-
cin B formulations, which overcome the toxic limi-
tations of the parent drug, were developed for the
treatment of systemic mycoses and are now also
used for the treatment of visceral leishmaniasis.
We have shown that they also have activity against
established T. cruzi Y strain infections in mice.
The activities of Amphotericin B liposomes
(AmBisomeÒ ), amphotericin B colloidal dispersion
(AmphocilÒ ) and amphotericin B lipid complex
(AbelcetÒ ) (see Hartsel & Bolard 1996) formula-
tions were compared with free drug in vitro against
intracellular amastigotes in Vero cells and macroph-
ages;  there was no significant variation of activity
against amastigotes in Vero cells but there was
variation in macrophages, probably due to differ-
ences in accumulation (Yardley & Croft, unpub-
lished). In vivo a single dose of  25 mg/kg or 12.5
mg/kg i.v. increased the survival time of all mice
significantly in comparison to controls, free drug
at the maximum tolerated  dose of 0.5 mg/kg, and
a dose of  6.25 mg/kg (Yardley & Croft, unpub-
lished). AmBisomeÒ  was best tolerated by infected
mice; the formulation also has a longer half-life
than parent compound (Proffitt et al. 1991). We
are currently examining the curative activity of this
formulation and its efficacy in a chronic model of
infection.
It is noteworthy that since the early publica-
tions on benznidazole and nifurtimox in the 1970’s
there has been little consideration of the pharma-
cokinetics of anti-T. cruzi drugs. With the continu-
ing interest in the potential of sterol biosynthesis
inhibitors for the treatment of Chagas disease
(Urbina 1997) some attention should be paid to
the pharmacokinetics of these drugs in T.cruzi in-
fected hosts. The variation of distribution and me-
tabolism of azoles has been considered in relation
to treatment of fungal infections (Hay 1993) as
have the pharmacokinetics of other sterol inhibi-
tors that have been suggested for combination
therapy (Urbina 1997), for example HMG-CoA
reductase inhibitors (Hamelin & Turgeon 1998) and
terbinafine (Faergemann 1997).
CONCLUSION
Experience with arsenicals for HAT and anti-
monials for leishmaniasis has shown how re-ex-
amination of pharmacokinetics can lead to new
drug regimes and improved therapy. A better un-
derstanding of the bioavailability and distribution
of drugs and the  local host physiology at the site
of infection, combined with an understanding of
the potential of drug design and drug delivery sys-
tems provides new opportunities for improving the
chemotherapy of the trypanosomiases.
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